

**Appendix Table F50. Domains of quality of life after oxybutynin treatments (individual RCTs)**

Reference	Active	Control	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95%CI)
<b>Personal relationship</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	8.4+/-16.8	11.6+/-22.1	-3.2 (-7.6; 1.2)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	10.4+/-17.3	8.4+/-16.8	2.0 (-1.7; 5.7)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	10.4+/-17.3	11.6+/-22.1	-1.2 (-5.6; 3.2)
<b>Social limitation</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	13.2+/-17.1	18.4+/-22.8	-5.2 (-9.7; -0.7)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	16.3+/-21.3	13.2+/-17.1	3.1 (-1.1; 7.3)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	16.3+/-21.3	18.4+/-22.8	-2.1 (-7.0; 2.8)
<b>Sleep/energy</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	17.9+/-18.9	21.1+/-22.8	-3.2 (-7.8; 1.4)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	18.2+/-19.2	17.9+/-18.9	0.3 (-3.8; 4.4)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	18.2+/-19.2	21.1+/-22.8	-2.9 (-7.6; 1.8)
<b>Role limitation</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	22.0+/-20.3	26.5+/-24.7	-4.5 (-9.5; 0.5)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	24.8+/-22.0	22.0+/-20.3	2.8 (-1.8; 7.4)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	24.8+/-22.0	26.5+/-24.7	-1.7 (-6.9; 3.5)
<b>Emotions</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	24.9+/-21.6	29.3+/-26.7	-4.4 (-9.8; 1.0)
<b>Physical limitation</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	26.6+/-22.8	29.7+/-27.3	-3.1 (-8.7; 2.5)

**Appendix Table F50. Domains of quality of life after oxybutynin treatments (individual RCTs) (continued)**

Reference	Active	Control	Active N	Control N	Active Mean+/- Standard Deviation	Control Mean+/- Standard Deviation	Mean Difference (95%CI)
<b>Emotions</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	28.2+/-25.8	24.9+/-21.6	3.3 (-1.9; 8.5)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	28.2+/-25.8	29.3+/-26.7	-1.1 (-6.9; 4.7)
<b>Physical limitation</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	29.7+/-25.6	26.6+/-22.8	3.1 (-2.2; 8.4)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	29.7+/-25.6	29.7+/-27.3	0.0 (-5.9; 5.9)
<b>General health</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	30.9+/-22.2	33.9+/-21.6	-3.0 (-7.8; 1.8)
<b>Incontinence impact</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 39cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	164	152	32.7+/-23.6	34.0+/-24.4	-1.3 (-6.6; 4.0)
<b>General health</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	33.4+/-20.3	30.9+/-22.2	2.5 (-2.1; 7.1)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	33.4+/-20.3	33.9+/-21.6	-0.5 (-5.2; 4.2)
<b>Incontinence impact</b>							
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 39cm <sup>2</sup>	160	164	34.6+/-23.2	32.7+/-23.6	1.9 (-3.2; 7.0)
Homma, 2006 <sup>309</sup>	Oxytrol-Oxybutynin transdermal patch 26cm <sup>2</sup>	Oxybutynin transdermal patch 52cm <sup>2</sup>	160	152	34.6+/-23.2	34.0+/-24.4	0.6 (-4.7; 5.9)
<b>Mean reduction in IIQ score</b>							
Dmochowski, 2002 <sup>276</sup>	Oxybutynin TDS, 2.6mg	Oxybutynin TDS3.9mg	133	125	-85.1+/-72.7	-64.2+/-82.9	-20.9 (-40.0; -1.8)